CAJ | 학술논문

目的：探讨恩替卡韦联合虎驹乙肝胶囊治疗HBeAg阳性慢乙肝的临床疗效。方法选取2011年1月～2014年1月我院收治的58例HBeAg阳性慢乙肝患者作为研究对象，采用随机数字表法将所选患者分为研究组和对照组，各29例，研究组给予恩替卡韦联合虎驹乙肝胶囊口服治疗，对照组给予恩替卡韦治疗，均检测肝功能、HBVM定量和血清HBV-DNA定量，综合比较两组患者12、24周时的血清HBeAg/HBeAb转换率、HBV-DNA转阴率。结果研究组12、24周时的血清HBeAg/HBeAb转换率分别为13.79%、48.28%，均优于对照组的3.45%、27.59%（P＜0.05）；两组患者12、24周时的HBV-DNA转阴率比较差异无统计学意义（P＞0.05）。结论恩替卡韦联合虎驹乙肝胶囊治疗HBeAg阳性慢乙肝患者效果确切，可有效降低或延缓肝病进展，增加生存率，值得临床广泛推广使用。
목적：탐토은체잡위연합호구을간효낭치료HBeAg양성만을간적림상료효。방법선취2011년1월～2014년1월아원수치적58례HBeAg양성만을간환자작위연구대상，채용수궤수자표법장소선환자분위연구조화대조조，각29례，연구조급여은체잡위연합호구을간효낭구복치료，대조조급여은체잡위치료，균검측간공능、HBVM정량화혈청HBV-DNA정량，종합비교량조환자12、24주시적혈청HBeAg/HBeAb전환솔、HBV-DNA전음솔。결과연구조12、24주시적혈청HBeAg/HBeAb전환솔분별위13.79%、48.28%，균우우대조조적3.45%、27.59%（P＜0.05）；량조환자12、24주시적HBV-DNA전음솔비교차이무통계학의의（P＞0.05）。결론은체잡위연합호구을간효낭치료HBeAg양성만을간환자효과학절，가유효강저혹연완간병진전，증가생존솔，치득림상엄범추엄사용。
Objective To investigate the effects of entecavir combined with HuJu Hepatitis B capsule for the treatment of HBeAg-positive chronic hepatitis B. Methods 58 cases with HBeAg-positive chronic hepatitis B in our hospital were randomly divided into a research group and a control group, 29 cases in each. The research group were treated with entecavir combined with HuJu capsule oral. The control group were treated with entecavir. Liver function, HBVM quantitative and quantitative serum HBV-DNA were detected. The serum HBeAg / HBeAb conversion rate, HBV-DNA negative rate during 12, 24 weeks were compared. Results The serum HBeAg / HBeAb conversion rate during 12,24 weeks of research group were respectively 13.79%, 48.28%, which were better than 3.45%, 27.59%of the control group(P < 0.05). HBV-DNA negative rate during 12,24 weeks of two groups had no statistical significance(P > 0.05). Conclusion Entecavir combined with HuJu capsule for the treatment of HBeAg-positive chronic hepatitis B has exact effect. It can effectively reduce or delay the progression of liver disease and increase survival rate, and is worthy of clinical widely used.